PYC Therapeutics (ASX:PYC) has announced the results of a study conducted in three-dimensional human models derived from patients with end-stage renal failure due to autosomal dominant polycystic kidney disease.
PYC Therapeutics says fourth candidate has potential in polycystic kidney disease
November 13, 2023 Australian Biotech
Latest Video
New Stories
-
Major brands and biosimilars feature prominently on November PBAC agenda
July 23, 2026 - - Latest News -
Bellberry and ASCEPT release checklist for 'new approach methodologies' trials
July 23, 2026 - - Latest News -
Faster processes could push Pharmac's options for investment backlog to 400 within two years
July 23, 2026 - - Latest News -
How national HPV vaccination programs are changing the story of cervical cancer
July 23, 2026 - - Latest News -
BLS and Trexapharm move to bring TREXAVIVE to Australian patients
July 22, 2026 - - BioPharma -
Radiopharm Theranostics reports positive results in tumour trials
July 22, 2026 - - Australian Biotech -
Proteomics International and Healius team up to take Promarker tests national
July 22, 2026 - - Australian Biotech

